Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Formela sold 26,587 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $15.08, for a total value of $400,931.96. Following the completion of the sale, the director owned 128,089 shares in the company, valued at $1,931,582.12. The trade was a 17.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jean Francois Formela also recently made the following trade(s):
- On Thursday, November 12th, Jean Formela sold 40,045 shares of Korro Bio stock. The stock was sold at an average price of $14.30, for a total value of $572,643.50.
- On Wednesday, August 26th, Jean Formela sold 300 shares of Korro Bio stock. The shares were sold at an average price of $13.96, for a total value of $4,188.00.
- On Wednesday, August 19th, Jean Formela sold 28,468 shares of Korro Bio stock. The shares were sold at an average price of $14.00, for a total value of $398,552.00.
Korro Bio Price Performance
NASDAQ:KRRO traded down $0.70 during trading hours on Friday, reaching $13.61. The company had a trading volume of 78,960 shares, compared to its average volume of 230,519. Korro Bio, Inc. has a 1-year low of $5.20 and a 1-year high of $17.35. The firm has a market cap of $186.87 million, a PE ratio of -1.50 and a beta of 3.23. The business’s 50 day moving average price is $11.86 and its 200-day moving average price is $12.16.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on KRRO shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Korro Bio in a research report on Tuesday, October 6th. Jefferies Financial Group set a $15.00 target price on Korro Bio in a research report on Tuesday, October 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, October 2nd. Finally, Wall Street Zen raised Korro Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Korro Bio has an average rating of “Buy” and an average price target of $17.29.
View Our Latest Report on Korro Bio
Institutional Investors Weigh In On Korro Bio
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Korro Bio during the second quarter worth $10,776,000. Nantahala Capital Management LLC acquired a new stake in shares of Korro Bio in the second quarter valued at about $8,699,274. Affinity Asset Advisors LLC acquired a new stake in shares of Korro Bio in the first quarter valued at about $8,002,000. ADAR1 Capital Management LLC acquired a new stake in shares of Korro Bio in the second quarter valued at about $7,118,000. Finally, Renaissance Technologies LLC increased its stake in shares of Korro Bio by 81.9% during the first quarter. Renaissance Technologies LLC now owns 136,227 shares of the company’s stock worth $1,542,000 after purchasing an additional 61,327 shares in the last quarter. Hedge funds and other institutional investors own 13.18% of the company’s stock.
About Korro Bio
Korro Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA-editing medicines intended to address genetic diseases by changing specific RNA sequences rather than altering a patient’s DNA. The company’s OPERA platform uses oligonucleotides to direct the body’s naturally occurring ADAR enzymes to edit targeted RNA. Korro has developed KRRO-110, an investigational candidate designed to correct a disease-associated RNA change linked to alpha-1 antitrypsin deficiency.
Featured Articles
- Five stocks we like better than Korro Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
